Abstract:Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm with rising incidence worldwide. Gremlin 1 (GREM1), a regulator of bone morphogenetic protein (BMP) signaling, fine-tunes extensive biological processes, including organ morphology, cellular metabolism, and multiple pathological developments. The roles of GREM1 in PDAC remain unknown. Methods: Varieties of public databases and online software were employed to analyze the expressions at transcription and protein levels of GREM1 in multiple malignant neoplasms including PDAC, and in addition, its potential pro-tumoral functions in PDAC were further evaluated. A total of 340 serum samples of pancreatic disease, including PDAC, low-grade malignant pancreatic neoplasm, benign pancreatic neoplasm, pancreatitis, and 132 healthy controls, were collected to detect GREM1. The roles of serum GREM1 in the diagnosis and prediction of survival of PDAC after radical resection were also analyzed. Results: Bioinformatics analyses revealed that GREM1 was overexpressed in PDAC and predicted a poorer survival in PDAC. A higher protein level of GREM1 in PDAC correlated with stroma formation and immunosuppression by recruiting varieties of immunosuppressive cells, including T regulatory cells (Tregs), M2 macrophages, myeloid-derived suppressor cells (MDSCs), and exhaustion T cells into the tumor microenvironment. A higher level of serum GREM1 was observed in PDAC patients, compared to healthy control ( p < 0.001). Serum GREM1 had a good diagnostic value (area under the curve (AUC) = 0.718, p < 0.001), and its combination with carbohydrate antigen 199 (CA199) achieved a better diagnostic efficacy (AUC = 0.914, p < 0.001), compared to CA199 alone. The cutoff value was calculated by receiver operating characteristic (ROC) analysis, and PDAC patients were divided into two groups of low and high GREM1. Logistic analyses showed serum GREM1 positively correlated with tumor size (hazard ratio (HR) = 7.097, p = 0.032) and histopathological grades (HR = 2.898, p = 0.014). High-level serum GREM1 (1,117.8 pg/ml) showed a shorter postoperative survival ( p = 0.0394). Conclusion: Higher intra-tumoral expression of GREM1 in PDAC contributes to tumor stroma and immunosuppressive tumor microenvironment, presenting its therapeutic potential. High-level serum GREM1 predicts poorer survival after resection. A combination of serum CA199 and GREM1 shows a stronger diagnostic efficacy in PDAC.

The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress TGFβ/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in urinary carcinoma

Methyl-CpG-binding Domain 3 Inhibits Epithelial–mesenchymal Transition in Pancreatic Cancer Cells Via TGF-β/Smad Signalling

Gremlin-1 Promotes Colorectal Cancer Cell Metastasis by Activating ATF6 and Inhibiting ATF4 Pathways

GREM1 is a potential biomarker for the progression and prognosis of bladder cancer

GREM1 Signaling in Cancer: Tumor Promotor and Suppressor?

GREM1 may be a biological indicator and potential target of bladder cancer

Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelial‐mesenchymal transition in colon cancer

Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer

Current status and prospects of GREM1 research in cancer (Review)

ENKUR Recruits FBXW7 to Ubiquitinate and Degrade MYH9 and Further Suppress MYH9‐induced Deubiquitination of Β‐catenin to Block Gastric Cancer Metastasis

Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression

Activation of Glucocorticoid Receptor Inhibits the Stem-Like Properties of Bladder Cancer Via Inactivating the Β-Catenin Pathway.

Gremlin1: a BMP antagonist with therapeutic potential in Oncology

TRIM65 Supports Bladder Urothelial Carcinoma Cell Aggressiveness by Promoting ANXA2 Ubiquitination and Degradation

GREM1 is Required to Maintain Cellular Heterogeneity in Pancreatic Cancer

A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis

Silencing Trim59 Inhibits Invasion/migration and Epithelial-to-mesenchymal Transition Via TGF-β/Smad2/3 Signaling Pathway in Bladder Cancer Cells

Overexpression of mircoRNA-137 inhibits cervical cancer cell invasion, migration and epithelial–mesenchymal transition by suppressing the TGF-β/smad pathway via binding to GREM1

GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma

GREM1 is Associated with Metastasis and Predicts Poor Prognosis in ER-negative Breast Cancer Patients

Gremlin1 is a Therapeutically Targetable FGFR1 Ligand That Regulates Lineage Plasticity and Castration Resistance in Prostate Cancer